NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form-3/?id=167838&from=3 CLASS PERIOD: May 7, 2025 ...

Market Outlook - The Federal Reserve's recent interest rate cuts and predictions for additional cuts are central to market discussions, with implications for various sectors [2][3] - Small-cap stocks are expected to outperform larger companies due to the benefits of lower capital costs, which are more impactful for smaller firms [3][4] Industry Trends - The home building industry has been sluggish, and there are concerns about whether lower mortgage rates will stimulate growth in this sector [5] - The market has been in a bull phase for nearly three years, with expectations that lower rates could further fuel this trend [6] Company Insights - Novo Nordisk has shown potential for recovery with the announcement of a successful oral weight loss pill, leading to a 6% stock increase, although it remains significantly below its previous highs [10][11] - Alphabet (Google) has gained momentum, with a 60% increase over the past year and positive developments regarding antitrust investigations, positioning it for further growth [12][15] - Nike is undergoing a turnaround under new leadership, with analysts beginning to upgrade their ratings, drawing parallels to McDonald's past recovery [16][18] - Fair Isaac Corporation (FICO) is viewed as a strong opportunity despite a 20% decline year-to-date, with potential benefits from a recovery in home building and lending [19][20]

By Maggie Fick VIENNA (Reuters) -Wegovy maker Novo Nordisk (NVO) has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly. The team, known internally as cardiometabolic educators, sat within Novo Nordisk's commercial division and included several hundred staff, sources said. The team was told last ...

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reu... ...

Novo Nordic shares popping 6% after better thanex than expected trial results from its so-called Wgoi pill. Angelica Peebles is here with more. So much coming out this week in the weight loss space.It has been quite a busy week, I can uh assure you that. But this data definitely impressing. So this was actually not presented at that conference but still coming amid this big week where we have all of these different presentations coming out of this diabetes conference in Vienna.But the headline here is that ...

Novo Nordic shares popping 6% after better thanex than expected trial results from its so-called Wgoi pill. Angelica Peebles is here with more. So much coming out this week in the weight loss space.It has been quite a busy week, I can uh assure you that. But this data definitely impressing. So this was actually not presented at that conference but still coming amid this big week where we have all of these different presentations coming out of this diabetes conference in Vienna.But the headline here is that ...

Group 1 - Novo Nordisk has been upgraded from 'Hold' to 'Buy' by Berenberg, with a revised price target of DKK425.00, indicating a potential 20% upside [1][2] - The upgrade follows a series of guidance downgrades after the company's mid-2024 share price peak, leading to a reset in market expectations [2] - Berenberg believes the shift in expectations allows for a more positive discussion regarding Novo Nordisk's growth prospects, valuation, and strategic catalysts, particularly in diabetes and obesity treatments [2][3] Group 2 - Berenberg has changed its sector preference, favoring Novo Nordisk over competitor Eli Lilly, citing Novo's potential for renewed momentum under new leadership [3] - Despite existing challenges, Berenberg sees opportunities for positive surprises and strategic wins that could enhance Novo Nordisk's position in the obesity drug market [3] - Novo Nordisk specializes in developing innovative medicines and delivery systems for chronic diseases, primarily focusing on diabetes, obesity, and rare blood and endocrine disorders [4]

Core Insights - Novo Nordisk and Eli Lilly have been among the top-performing healthcare stocks, with Novo Nordisk increasing by 400% and Eli Lilly by 67% over the past five years, despite a recent sell-off in Novo Nordisk's value [1][2] Group 1: Market Position and Growth Potential - Both companies are considered underrated despite their significant past performance, indicating potential for further investment [2] - The market for GLP-1 weight loss drugs is rapidly expanding, with many pharmaceutical companies developing treatments, presenting a substantial growth opportunity [4] - Eli Lilly and Novo Nordisk hold a competitive advantage as they already have approved GLP-1 treatments on the market: Zepbound and Wegovy [5] Group 2: Pricing and Accessibility - The high cost of GLP-1 drugs, with Zepbound priced over $1,000 and Wegovy over $1,300 for a 28-day supply, poses a barrier for consumers without insurance [5][9] - The Trump administration is reportedly considering covering GLP-1 weight loss drugs under Medicare and Medicaid, which could significantly boost market growth for these companies [6][9] Group 3: Broader Health Benefits - GLP-1 drugs are linked to various health benefits beyond weight loss, including treatment for obstructive sleep apnea and reducing the risk of serious heart problems in obese adults [7] - Ongoing research may uncover additional applications for GLP-1 drugs, potentially leading to stronger growth rates for both companies [10]

Core Insights - The U.S. FDA's enforcement action against drug promotion raises concerns for ETFs with exposure to weight-loss treatment manufacturers [1][3] - Eli Lilly and Novo Nordisk are under scrutiny for not properly disclosing safety concerns related to their GLP-1 weight-loss medications [2][5] - Hims & Hers faces allegations of false marketing claims regarding non-FDA-approved compounded semaglutide products [2][3] Company-Specific Summary - Eli Lilly and Novo Nordisk are major players in the weight-loss medication sector, with their products Mounjaro, Zepbound, and Wegovy being highlighted in media discussions without adequate safety disclosures [2][5] - Hims & Hers is implicated in misleading marketing practices, which could impact its reputation and stock performance [2][4] Industry Impact - The regulatory scrutiny could negatively affect ETFs like the Amplify Weight Loss Drug & Treatment ETF (THNR), which holds significant positions in Eli Lilly and Novo Nordisk, as well as Hims & Hers [3][6] - Other ETFs, such as Global X HealthTech ETF (HEAL) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH), may also face indirect pressure due to the regulatory environment surrounding obesity treatments [4][6] - The increased monitoring by the FDA highlights the volatility risk associated with thematic funds focused on weight-loss medications [5][6]

Core Insights - Novo Nordisk's market value increased by approximately £9 billion following positive research results for its new anti-obesity pill, which shows weight loss comparable to its injectable Wegovy [1] - The company is competing with Eli Lilly to launch an oral treatment, with Novo's shares rising over 6% due to expectations of regaining market share lost to Eli Lilly and cheaper generic GLP-1 drugs [1] Company Performance - Novo Nordisk's shares had previously fallen nearly 60% over the past year due to slowing sales and multiple profit warnings, leading to plans for 9,000 layoffs by the new CEO Mike Doustdar [2] - The new once-daily pill version of Wegovy demonstrated significant weight loss in clinical trials, with nearly one in three participants losing 20% or more of their body weight [2][3] Clinical Trials and FDA Approval - The oral GLP-1 drug is the first of its kind submitted to the FDA, with a decision expected by the end of the year; production has already commenced at Novo's US facilities [3] - In a 64-week late-stage trial with 307 obese or overweight adults, participants lost an average of 16.6% of their body weight [3] Competitive Landscape - Novo Nordisk is in direct competition with Eli Lilly's orforglipron, which reported that one in five participants lost 20% or more of their weight over 72 weeks in a trial involving 3,127 adults [4] - Analysts project peak sales of $10 billion annually for Eli Lilly's orforglipron, with some estimates reaching up to $25 billion [5] Market Potential - UBS analysts forecast peak annual sales of $5 billion for Novo's oral obesity pill, with $4 billion expected from the US market, where 40% of the population is obese [6] - The oral versions of these drugs are anticipated to be more accessible and cost-effective, potentially allowing millions more individuals to manage obesity [7] Industry Trends - The performance of GLP-1 drugmakers has significantly outpaced that of pharmaceutical companies not involved in weight loss drug production [8]